Authors

Thai H. Ho, MD, PhD, Mayo Clinic Arizona

Latest:

Growing Body of Evidence Supports Use of HIPEC in Ovarian Cancer

A large pool of evidence exists to support the use of HIPEC in ovarian cancer, and hyperthermic and other novel intraperitoneal chemotherapies should continue to be incorporated into novel clinical trial designs.

Theodore H. Welling MD

Latest:

Dr. Welling on SIRT in Patients With Hepatobiliary Neoplasms

Theodore H. Welling MD, associate professor, department of Surgery, director, Liver Tumor Program, NYU Langone’s Perlmutter Cancer Center, discusses the use of selective internal radiation therapy (SIRT) in patients with hepatobiliary cancers.

Theodore S. Hong, MD

Latest:

Dr. Hong on High-Dose Hypofractionated Proton Beam Therapy for Liver Cancer

Theodore S. Hong, MD, director, Gastrointestinal Service, Department of Radiation Oncology, discusses high-dose hypofractionated proton beam therapy for unresectable primary liver cancers.

Theresa Keegan, PhD, MS

Latest:

Second Cancers Can Wield Greater Impact on Adolescent and Young Adult Survivors

Advances in treatment and supportive care have resulted in substantial improvements in cancer survival and a growing number of cancer survivors in the United States.

Theresa Marcus

Latest:

The C Letter Word

Hematology/oncology fellowship coordinator, Theresa Marcus, reflects on what it was like to receive a diagnosis of cancer, experience recurrence, and later learn that she had finally become cancer-free with the help of her colleagues.

Theresa Shao, MD

Latest:

Dr. Shao on Prognosis of Patients With HER2+ Breast Cancer

Theresa Shao, MD, assistant professor of hematology-oncology, Icahn School of Medicine, Tisch Cancer Institute, Mount Sinai Health System, discusses the prognosis of patients with HER2-positive breast cancer.

Thierry Andre, MD

Thierry André, MD, is a professor of Medical Oncology at the Sorbonne Université and head of the Medical Oncology Department at the Saint Antoine Hospital in Paris, France.

Latest:

Dr André on the Safety Profile of Nivolumab/Ipilimumab in MSI-H/dMMR Metastatic CRC

Thierry André, MD, discusses the safety profile of nivolumab/ipilimumab for the treatment of patients with MSI-H/dMMR metastatic colorectal cancer.

Thierry Conroy, MD

Latest:

Dr. Conroy on the Findings With Adjuvant mFOLFIRINOX in Pancreatic Cancer

Thierry Conroy, MD, medical oncologist, director, Institut de Cancerologie de Lorraine, discusses the findings with an adjuvant a modified FOLFIRINOX regimen in patients with nonmetastatic pancreatic ductal adenocarcinoma.

Thierry Jahan, MD

Latest:

Dr. Thierry Jahan on CRS-207 With Chemotherapy in Mesothelioma

Thierry Jahan, MD, professor of medicine at the UCSF Helen Diller Family Comprehensive Cancer Center in San Francisco, discusses CRS-20, a live, attenuated Listeria monocytogenes bacterium which is being investigated with chemotherapy in malignant pleural mesothelioma (MPM).

Thierry M. Jahan, MD

Latest:

Dr. Thierry Jahan on the CRS-207 Vaccine in Mesothelioma

Thierry M. Jahan, MD, a clinical professor in the Department of Medicine at the University of California San Francisco Helen Diller Family Comprehensive Cancer Center, discusses a phase Ib trial of CRS-207 in malignant pleural mesothelioma (MPM).

Thomas A. Abrams, MD, Harvard Medical School

Latest:

Dr. Abrams on Next Steps for Cabozantinib/Atezolizumab Combo in MSS/MMRp CRC

Thomas A. Abrams, MD, discusses the next steps for exploration of cabozantinib plus atezolizumab in the treatment of microsatellite stable and mismatch repair proficient colorectal cancer.

Thomas A. Hensing, MD

Latest:

Dr. Hensing Discusses Studies in Stage III NSCLC

Thomas A. Hensing, MD, co-director of the Thoracic Oncology Program at NorthShore University HealthSystem, discusses prospective studies in stage III non-small cell lung cancer (NSCLC).

Thomas A. Hope, MD

Latest:

Dr. Hope on Challenges With 68Ga-PSMA-11 PET in Prostate Cancer

Thomas Hope, MD, discusses challenges with 68Ga-PSMA-11 PET in men with intermediate- or high-risk prostate cancer.

Thomas A. Neville, PhD

Latest:

Thomas A. Neville, PhD, Discusses PSA Growth Rate

Thomas A. Neville, PhD, CEO of Soar Biodynamics in Incline Village, Nevada, discusses PSA growth rate.

Thomas Butler, MD

Latest:

Dr. Butler on the Importance of Health Literacy Initiatives

Thomas Butler, MD, associate professor of interdisciplinary clinical oncology, Mitchell Cancer Center, discusses the importance of health literacy initiatives at the Association of Community Cancer Center (ACCC) National Oncology Conference.

Thomas C. Krivak, MD

Latest:

Optimizing Therapy for MMR-Proficient Endometrial Cancer

Panelists discuss how the DUO trial demonstrates the benefit of durvalumab in adjuvant endometrial cancer treatment and suggests potential value of adding olaparib in specific subgroups like mismatch repair–proficient patients, though emphasizing the need for confirmatory studies before routine clinical implementation.

Thomas D. Coates, MD

Thomas D. Coates, MD, University of Southern California Keck School of Medicine

Thomas E. Hutson, DO, Pharm.D., FACP

Latest:

An Individualized Approach to Treating Advanced RCC

Grounded in a collaborative and personalized approach, researcher and clinician Dr. Thomas Hutson expands on his best practices for treating certain people living with advanced RCC with a combination therapy.